Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03400488 · ClinicalTrials.gov registry record · Phase 1

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5718 After Single and Multiple Ascending Dose Administration to Healthy Japanese Men

A Phase 1 study of Coronary Artery Disease, sponsored by AstraZeneca.

Completed
Registry status
Phase 1
Development phase
32
Enrollment target
1
Study location

NCT03400488 is a Phase 1 study of Coronary Artery Disease that has completed, run by AstraZeneca. The registered enrollment target is 32 participants, below the 1,287-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03400488, a Phase 1 study of Coronary Artery Disease, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
Phase 1
Development phase
32 participants
Enrollment target
1
Study location

Study Summary

This is a Phase I study to investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of the novel compound, AZD5718 in healthy Japanese men. The results from this study will form the basis for decisions on future studies.

Conditions Studied

Interventions

  • DRUG AZD5718 oral suspension
  • OTHER Placebo matching AZD5817 oral suspension

Study Locations (1)

California

  • Research Site - Glendale

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2018-01-16
Est. Completion 2018-06-12
Phase Phase 1

Sponsor

AstraZeneca

1,285 total trials

What the Registry Record Tells You About NCT03400488

The ClinicalTrials.gov registry entry for NCT03400488 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,287-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (98% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Coronary Artery Disease appearing as the primary indexed condition, and to 2 interventions - of which AZD5718 oral suspension is the first listed.

NCT03400488 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT03400488 about?

NCT03400488 is a clinical study titled "A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5718 After Single and Multiple Ascending Dose Administration to Healthy Japanese Men". This is a Phase I study to investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of the novel compound, AZD5718 in healthy Japanese men. The results from this study will form the basis for decisions on future studies.

What is the current status of trial NCT03400488?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2018-01-16. Estimated completion is 2018-06-12.

What conditions does trial NCT03400488 study?

This clinical trial studies the following conditions: Coronary Artery Disease.

What interventions are being tested in trial NCT03400488?

The interventions under investigation include: AZD5718 oral suspension (DRUG), Placebo matching AZD5817 oral suspension (OTHER).

Who is sponsoring clinical trial NCT03400488?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03400488 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Coronary Artery Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.